These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23301520)

  • 1. Pharmacokinetic evaluation of capecitabine in breast cancer.
    Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine in breast cancer: current status.
    Smorenburg CH; Bontenbal M; Verweij J
    Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine: effective oral fluoropyrimidine chemotherapy.
    McKendrick J; Coutsouvelis J
    Expert Opin Pharmacother; 2005 Jun; 6(7):1231-9. PubMed ID: 15957975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rational development of capecitabine from the laboratory to the clinic.
    Pentheroudakis G; Twelves C
    Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving forward with capecitabine: a glimpse of the future.
    Biganzoli L; Martin M; Twelves C
    Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
    Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):571-2. PubMed ID: 12503818
    [No Abstract]   [Full Text] [Related]  

  • 9. Capecitabine in advanced gastric cancer.
    Okines A; Chau I; Cunningham D
    Expert Opin Pharmacother; 2007 Nov; 8(16):2851-61. PubMed ID: 17956204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of capecitabine: a review.
    Mikhail SE; Sun JF; Marshall JL
    Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine in carcinoma of the pancreas.
    Smith DB; Neoptolemos JP
    Expert Opin Pharmacother; 2006 Aug; 7(12):1633-9. PubMed ID: 16872266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational development of capecitabine.
    Venturini M
    Eur J Cancer; 2002 Feb; 38 Suppl 2():3-9. PubMed ID: 11841929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor specific therapy. Targeted breast cancer therapy].
    MMW Fortschr Med; 2003 Sep; 145(38):62. PubMed ID: 14603691
    [No Abstract]   [Full Text] [Related]  

  • 15. Capecitabine: in advanced gastric or oesophagogastric cancer.
    Dhillon S; Scott LJ
    Drugs; 2007; 67(4):601-10. PubMed ID: 17352519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
    Tsukamoto Y; Kato Y; Ura M; Horii I; Ishitsuka H; Kusuhara H; Sugiyama Y
    Pharm Res; 2001 Aug; 18(8):1190-202. PubMed ID: 11587492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    Sternberg CN; Reichardt P; Holland M
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
    Minami H; Ebi H
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
    Bar-Sela G; Haim N
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine in the treatment of colorectal cancer.
    O'Neill VJ; Cassidy J
    Future Oncol; 2005 Apr; 1(2):183-90. PubMed ID: 16555988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.